Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
?
4-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
?
benzene-1,2-diol + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
-
-
-
?
L-dopa + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
-
-
-
?
S-adenosyl-L-methionine + (3,4-dihydroxyphenyl)acetic acid
S-adenosyl-L-homocysteine + (4-hydroxy-3-methoxyphenyl)acetic acid + (3-hydroxy-4-methoxyphenyl)acetic acid
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxybenzaldehyde
S-adenosyl-L-homocysteine + 4-hydroxy-3-methoxybenzaldehyde + 3-hydroxy-4-methoxybenzaldehyde
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxybenzoic acid
S-adenosyl-L-homocysteine + 4-hydroxy-3-methoxybenzoic acid + 3-hydroxy-4-methoxybenzoic acid
-
-
-
?
S-adenosyl-L-methionine + 4-nitrobenzene-1,2-diol
S-adenosyl-L-homocysteine + 2-methoxy-4-nitrophenol + 2-methoxy-5-nitrophenol
-
-
-
?
S-adenosyl-L-methionine + a catechol
S-adenosyl-L-homocysteine + a guaiacol
-
-
-
?
S-adenosyl-L-methionine + epinephrine
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + norepinephrine
S-adenosyl-L-homocysteine + ?
-
-
-
?
(+)-catechin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
3'-O-methyl derivatives are consistently the main metabolites, 3'-O-methyl derivatives are consistently the main metabolites, meta/para ratio of the metabolites is approximately 25:1
-
?
(-)-epicatechin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
3'-O-methyl derivatives are consistently the main metabolites, the meta/para ratio of the metabolites is approximately 6:1
-
?
1-carboxy-1-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
1-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
2-hydroxyestrogen + S-adenosyl-L-methionine
2-methoxyestrogen + S-adenosyl-L-homocysteine
-
-
-
-
?
3,4-dihydroxybenzoic acid + S-adenosyl-L-methionine
4-hydroxy-3-methoxybenzoic acid + S-adenosyl-L-homocysteine
-
-
the meta/para ratio of the metabolites is approximately 4.5
-
?
3,4-dihydroxybenzoic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
3,4-dihydroxymandelic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
3,4-dihydroxyphenylacetic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
4-hydroxyestrogen + S-adenosyl-L-methionine
4-methoxyestrogen + S-adenosyl-L-homocysteine
-
-
-
-
?
adrenaline + S-adenosyl-L-methionine
methanephrine + S-adenosyl-L-homocysteine
-
-
-
-
?
adrenaline + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
benzene-1,2-diol + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
-
-
-
-
?
catechol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
DL-3,4-dihydroxyamphetamine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
DL-3,4-dihydroxyephedrine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
dopamine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
epinephrine + S-adenosyl-L-methionine
metanephrine + S-adenosyl-L-homocysteine
-
-
-
?
epinine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
L-dopa + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
-
-
-
-
?
L-dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 3-O-methyl-L-dopa
-
-
-
-
?
L-Dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 3-O-methyldopa
-
-
-
-
?
norepinephrine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + normetanephrine
-
-
-
-
?
p-nitrocatechol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
procyanidin dimer B1 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B2 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B3 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B4 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B5 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B7 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin trimer C1 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated, dimethylated, and trimethylated C1 metabolites
-
?
S-adenosyl-L-homocysteine + 4''-O-methyl epigallocatechin gallate
S-adenosyl-L-homocysteine + 4',4''-di-O-methyl epigallocatechin gallate
-
-
-
-
?
S-adenosyl-L-methionine + 2-hydroxyestradiol
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxy-L-Phe
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxybenzoic acid
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + a catechol
?
-
-
-
-
?
S-adenosyl-L-methionine + epigallocatechin
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + epigallocatechin gallate
S-adenosyl-L-homocysteine + 4''-O-methyl epigallocatechin gallate
-
-
-
-
?
S-adenosyl-L-methionine + epinephrine
S-adenosyl-L-homocysteine + metanephrine
-
-
-
-
?
S-adenosyl-L-methionine + L-Dopa
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + norepinephrine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + norepinephrine
S-adenosyl-L-homocysteine + normetanephrine
-
-
-
-
?
salvianolic acid B + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
tolcapone + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
substrate of both isoform S-COMT and isoform MB-COMT
-
-
?
additional information
?
-
additional information
?
-
-
not: monophenols
-
-
?
additional information
?
-
-
not: monophenols
-
-
?
additional information
?
-
-
strict requirement for S-adenosyl-L-methionine as methyl donor and a catechol as acceptor substrate
-
-
?
additional information
?
-
-
physiological role is the inactivation of catecholamine hormones and neurotransmitters as well as detoxification of a variety of xenobiotic amines and drugs
-
-
?
additional information
?
-
-
membrane protein and (or) lipid components may play an important role in catecholamine metabolism
-
-
?
additional information
?
-
-
primary role in extraneuronal inactivation of endogenous catecholamines and in the further metabolism of oxidized catecholamine metabolites
-
-
?
additional information
?
-
-
COMT in the adrenal gland might not be related to blood pressure regulation
-
-
?
additional information
?
-
-
degree and position of methylation depend clearly on the three-dimensional structure of the entire substrate molecule
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(-)-epigallocatechin-3-O-gallate
potent non-competitive inhibitor
4'-fluoro-4,5-dihydroxy-biphenyl-3-carboxylic acid [(E)-3-[(2S,4R,5R)-4-hydroxy-5-(6-methyl-purin-9-yl)-tetrahydro-furan-2-yl]-allyl]-amide
-
4'-fluoro-4,5-dihydroxy-biphenyl-3-carboxylic acid [(E)-3-[(2S,4R,5R)-4-hydroxy-5-(6-methylamino-purin-9-yl)-tetrahydro-furan-2-yl]-allyl]-amide
-
4-phenyl-7,8-dihydroxycoumarin
-
9-[(5E)-3,5,6,7-tetradeoxy-3-fluoro-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-xylo-hept-5-enofuranosyl]-N6-methyladenine
-
9-[(5E)-3,5,6,7-tetradeoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-3-methyl-beta-D-xylo-hept-5-enofuranosyl]-N6-propyladenine
-
N-[(2E)-3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(methylamino)-9H-purin-9-yl]tetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(propylamino)-9H-purin-9-yl]tetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-ethyl-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-[6-(cyclopropylamino)-9H-purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-[6-(ethylamino)-9H-purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
N-[(2E)-3-[(2S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
(2E)-4,7-anhydro-1,2,3-trideoxy-1-(2,3-dihydroxy-5-nitrobenzamido)-L-ribo-hept-2-enitol
-
-
1-Carboxysalsoline
-
i.e. 1-carboxy-1-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline, competitive inhibition of 3,4-dihydroxybenzoic acid methylation
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-4-(trifluoromethyl)-1H-imidazole
-
-
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]benzo[d]imidazole
-
-
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]pyridin-4(1H)-one
-
-
1-[1-(2-chlorobenzyl)-1H-benzimidazol-4-yl]-3-hydroxypyridin-4(1H)-one
-
-
1-[3,4-dihydroxy-5-nitrophenyl]-2-phenyl-ethanone
-
-
1-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
-
-
3,4,5-trihydroxypyrogallol
-
liver homogenate, 0.03 mM inhibitor: 0.8% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
3,5-dinitrocatechol
-
liver S-COMT, 50% inhibition at 74 nM
3-fluoro-4-[1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]benzene-1,2-diol
-
liver homogenate, 0.03 mM inhibitor: 32.3% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
3-nitro-5-(1-p-tolyl-1H-pyrazol-5-yl)benzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
3-nitro-5-(1-phenyl-1H-pyrazol-5-yl)benzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
3-nitro-5-(1H-pyrazol-5-yl)benzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
4-(1-phenyl-1H-pyrazol-5-yl)benzene-1,2,3-triol
-
liver homogenate, 0.03 mM inhibitor: 26.8% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
4-(5-(3,4-dihydroxy-5-nitrophenyl)-1H-pyrazol-1-yl)benzonitrile
-
liver homogenate, 0.003 mM inhibitor: 0.3% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
4-[1-(4-methylphenyl)-1H-pyrazol-5-yl]benzene-1,2-diol
-
liver homogenate, 0.03 mM inhibitor: 41.2% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
4-[4-(4-chlorophenyl)-5-methyl-1H-pyrazol-3-yl]benzene-1,2,3-triol
-
liver homogenate, 0.003 mM inhibitor: 15.6% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
5-(1-methyl-1H-pyrazol-5-yl)-3-nitrobenzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 1.1% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
5-hydroxy-1-[3-(isoquinolin-4-yl)phenyl]-2-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-4(1H)-one
-
-
5-Substituted 3-hydroxy-4-methoxybenzaldehydes
-
-
5-Substituted 3-hydroxy-4-methoxybenzoic acids
-
-
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-imidazo[4,5-c]pyridine
-
-
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-pyrrolo[3,2-c]pyridine
-
-
5-[1-(3-chlorophenyl)-1H-pyrazol-5-yl]-2,3-dihydroxybenzoic acid
-
liver homogenate, 0.03 mM inhibitor: 24.1% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
5-[1-(3-chlorophenyl)-1H-pyrazol-5-yl]-3-nitrobenzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
5-[1-(3-chlorophenyl)-4-phenyl-1H-pyrazol-5-yl]-3-nitrobenzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 68.6% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
6-methyl-9-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]purine
-
-
9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]purine
-
-
Analogs of S-adenosyl-L-homocysteine
-
overview: inhibition of the liver, heart and brain enzyme
beta-thujaplicin
-
70-100% inhibition at 0.2 mM
flavonoids
-
overview: relationship between structure and ability to inhibit
high ionic strength
-
-
-
N-ethyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
-
-
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-1,2,4-triazole-3-carboxamide
-
-
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
-
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
-
N6-methyl-9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]adenine
-
-
norepinephrine
-
0.01 mM, 41% inhibition of 2-hydroxyestradiol methylation
OR-462
-
disubstituted catechol
OR486
-
depressed COMT activity results in enhanced mechanical and thermal pain sensitivity
p-chloromercuribenzoate
-
-
p-hydroxymercuribenzoate
-
70-100% inhibition at 0.2 mM
Polyphenolic compounds
-
-
-
pyridin-4-yl (5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-1-thio-beta-D-ribo-hept-5-enofuranoside
-
-
quercetin
-
0.01 mM, 90% inhibition of 2-hydroxyestradiol methylation
Ro41-0960
-
depressed COMT activity results in enhanced mechanical and thermal pain sensitivity
S-adenosyl-L-homocysteine
-
-
salvianolic acid B
-
weak inhibitor. In vivo, a single intravenous dose of salvianolic acid B decreases the plasma concentration of 3-O-methyldopa, with no obvious effect on the pharmacokinetics of L-dopa
tolcapone
-
strongly inhibits the formation of 3-methylsalvianolic acid B in vitro and in vivo, without any change in its plasma concentration. Tolcapone significantly increases the cumulative bile excretion of salvianolic acid from 3% to 40% in the rat
[5-(3,4-dihydroxy-5-nitrophenyl)-4-phenyl-1H-pyrazol-1-yl](4-methylphenyl)methanone
-
liver homogenate, 0.003 mM inhibitor: 2.8% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
Mg2+
-
inhibition above 2 mM
Mg2+
-
required for activity
N-ethylmaleimide
-
-
N-ethylmaleimide
-
70-100% inhibition at 0.2 mM
pyrogallol
-
-
pyrogallol
-
70-100% inhibition at 0.2 mM
Salsolidine
-
-
Salsolidine
-
i.e. 1-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline, competitive inhibition of 3,4-dihydroxybenzoic acid methylation
tropolone
-
-
tropolone
-
70-100% inhibition at 0.2 mM
additional information
COMT is a target for inhibitor development aiming at Parkinsons disease treatment and is submitted to extensive structure-based drug design
-
additional information
-
inhibition by analogs of S-adenosyl-homcysteine
-
additional information
-
relationship between the structure of flavonoids and their inhibitory activity
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.007022
(2E)-4,7-anhydro-1,2,3-trideoxy-1-(2,3-dihydroxy-5-nitrobenzamido)-L-ribo-hept-2-enitol
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.44
1-Carboxysalsoline
-
-
0.004645
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-4-(trifluoromethyl)-1H-imidazole
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.014
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]benzo[d]imidazole
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0749
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]pyridin-4(1H)-one
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000019
1-[3,4-dihydroxy-5-nitrophenyl]-2-phenyl-ethanone
-
-
0.0024
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-imidazo[4,5-c]pyridine
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.002378
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-pyrrolo[3,2-c]pyridine
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000001
6-methyl-9-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]purine
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000034
9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]purine
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0104
N-ethyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0156
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-1,2,4-triazole-3-carboxamide
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0199
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000002
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000007
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000007
N6-methyl-9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]adenine
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000132
pyridin-4-yl (5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-1-thio-beta-D-ribo-hept-5-enofuranoside
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.022 - 0.04
S-adenosyl-L-homocysteine
-
-
0.0021
salvianolic acid B
-
37°C, pH not specified in the publication
0.0053
RO-4-4602
-
plus norepinephrine
0.007
RO-4-4602
-
plus dopamine
0.009
RO-4-4602
-
plus epinephrine
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0012
(-)-epigallocatechin-3-O-gallate
0.001368
4'-fluoro-4,5-dihydroxy-biphenyl-3-carboxylic acid [(E)-3-[(2S,4R,5R)-4-hydroxy-5-(6-methyl-purin-9-yl)-tetrahydro-furan-2-yl]-allyl]-amide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.001858
4'-fluoro-4,5-dihydroxy-biphenyl-3-carboxylic acid [(E)-3-[(2S,4R,5R)-4-hydroxy-5-(6-methylamino-purin-9-yl)-tetrahydro-furan-2-yl]-allyl]-amide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000011
9-[(5E)-3,5,6,7-tetradeoxy-3-fluoro-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-xylo-hept-5-enofuranosyl]-N6-methyladenine
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000025
9-[(5E)-3,5,6,7-tetradeoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-3-methyl-beta-D-xylo-hept-5-enofuranosyl]-N6-propyladenine
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.02 - 0.039
epigallocatechin
0.000011
N-[(2E)-3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(methylamino)-9H-purin-9-yl]tetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000026
N-[(2E)-3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(propylamino)-9H-purin-9-yl]tetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000009
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000035
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000236
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-ethyl-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000082
N-[(2E)-3-[(2R,3S,4R,5R)-5-[6-(cyclopropylamino)-9H-purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000043
N-[(2E)-3-[(2R,3S,4R,5R)-5-[6-(ethylamino)-9H-purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.028
N-[(2E)-3-[(2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.00004
N-[(2E)-3-[(2S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0022 - 0.0045
quercetin
0.0316
(2E)-4,7-anhydro-1,2,3-trideoxy-1-(2,3-dihydroxy-5-nitrobenzamido)-L-ribo-hept-2-enitol
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0209
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-4-(trifluoromethyl)-1H-imidazole
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0628
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]benzo[d]imidazole
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.336
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]pyridin-4(1H)-one
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0000265 - 0.000881
1-[1-(2-chlorobenzyl)-1H-benzimidazol-4-yl]-3-hydroxypyridin-4(1H)-one
0.0000274 - 0.000237
1-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
0.000013 - 0.000565
5-hydroxy-1-[3-(isoquinolin-4-yl)phenyl]-2-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-4(1H)-one
0.0108
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-imidazo[4,5-c]pyridine
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0107
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-pyrrolo[3,2-c]pyridine
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000006
6-methyl-9-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]purine
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000155
9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]purine
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0468
N-ethyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0703
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-1,2,4-triazole-3-carboxamide
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0895
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000009
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000031
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000032
N6-methyl-9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]adenine
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000596
pyridin-4-yl (5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-1-thio-beta-D-ribo-hept-5-enofuranoside
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0012
(-)-epigallocatechin-3-O-gallate
Rattus norvegicus
O-methylation of 2-hydroxyestradiol
0.0012
(-)-epigallocatechin-3-O-gallate
Rattus norvegicus
O-methylation of 4-hydroxyestradiol
0.012
catechin
Rattus norvegicus
O-methylation of 4-hydroxyestradiol
0.019
catechin
Rattus norvegicus
O-methylation of 2-hydroxyestradiol
0.019
epicatechin
Rattus norvegicus
O-methylation of 4-hydroxyestradiol
0.04
epicatechin
Rattus norvegicus
O-methylation of 2-hydroxyestradiol
0.02
epigallocatechin
Rattus norvegicus
O-methylation of 4-hydroxyestradiol
0.039
epigallocatechin
Rattus norvegicus
O-methylation of 2-hydroxyestradiol
0.0021
fisetin
Rattus norvegicus
O-methylation of 4-hydroxyestradiol
0.0035
fisetin
Rattus norvegicus
O-methylation of 2-hydroxyestradiol
0.0022
quercetin
Rattus norvegicus
O-methylation of 4-hydroxyestradiol
0.0045
quercetin
Rattus norvegicus
O-methylation of 2-hydroxyestradiol
0.0000265
1-[1-(2-chlorobenzyl)-1H-benzimidazol-4-yl]-3-hydroxypyridin-4(1H)-one
Rattus norvegicus
-
isoform MB-COMT, pH 7.4, 37°C
0.000881
1-[1-(2-chlorobenzyl)-1H-benzimidazol-4-yl]-3-hydroxypyridin-4(1H)-one
Rattus norvegicus
-
isoform S-COMT, pH 7.4, 37°C
0.0000274
1-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
Rattus norvegicus
-
isoform MB-COMT, pH 7.4, 37°C
0.000237
1-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
Rattus norvegicus
-
isoform S-COMT, pH 7.4, 37°C
0.000013
5-hydroxy-1-[3-(isoquinolin-4-yl)phenyl]-2-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-4(1H)-one
Rattus norvegicus
-
isoform MB-COMT, pH 7.4, 37°C
0.000565
5-hydroxy-1-[3-(isoquinolin-4-yl)phenyl]-2-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-4(1H)-one
Rattus norvegicus
-
isoform S-COMT, pH 7.4, 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Axelrod, J.; Tomchick, R.
Enzymatic O-methylation of epinephrine and other catechols
J. Biol. Chem.
233
702-705
1958
Bos taurus, Cavia porcellus, Oryctolagus cuniculus, Homo sapiens, Mus musculus, Rattus norvegicus, Sus scrofa
brenda
Huh, M.M.O.; Friedhoff, A.J.
Multiple molecular forms of catechol-O-methyltransferase. Evidence for two distinct forms, and their purification and physical characterization
J. Biol. Chem.
254
299-308
1979
Oryctolagus cuniculus, Homo sapiens, Rattus norvegicus
brenda
Borchardt, R.T.
Catechol O-methyltransferase
Methods Enzymol.
77
267-272
1981
Rattus norvegicus
brenda
Lundstrm, K.; Tilgmann, C.; Pernen, J.; Kalkkinen, N.; Ulmanen, I.
Expression of enzymatically active rat liver and human placental catechol-O-methyltransferase in Escherichia coli; purification and partial characterization of the enzyme
Biochim. Biophys. Acta
1129
149-154
1992
Homo sapiens, Rattus norvegicus
brenda
Borchardt, R.T.; Cheng, C.F.
Purification and characterization of rat heart and brain catechol methyltransferase
Biochim. Biophys. Acta
522
49-62
1978
Rattus norvegicus
brenda
Tong, J.H.; D'Iorio, A.
Solubilization and partial purification of particulate catechol-O-methyltransferase from rat liver
Can. J. Biochem.
55
1108-1113
1977
Rattus norvegicus
brenda
Buu, N.T.; Kuchel, O.; Parent, M.T.
Competitive inhibition of catechol O-methyltransferase by RO-4-4602
Can. J. Biochem.
55
771-773
1977
Rattus norvegicus
brenda
Borchardt, R.T.; Cheng, C.F.; Thakker, D.R.
Purification of catechol-O-methyltransferase by affinity chromatography
Biochem. Biophys. Res. Commun.
63
69-77
1975
Rattus norvegicus
brenda
Sanft, K.; Thomas, H.
Competitive inhibition of catechol-O-methyltransferase by tetrahydro-isochinoline alkaloids salsolidin and 1-carboxysalsolin
Z. Naturforsch. C
44
173-176
1989
Rattus norvegicus
brenda
Schwabe, K.P.; Flohe, L.
Catechol-O-methyltransferase, 3. Relationship between the structure of flavonoids and their ability to inhibit catechol-O-methyltransferase
Hoppe-Seyler's Z. Physiol. Chem.
353
476-482
1972
Rattus norvegicus
brenda
Coward, J.K.; Slisz, E.P.; Wu, F.Y.H.
Kinetic studies on catechol O-methyltransferase. Product inhibition and the nature of the catechol binding site
Biochemistry
12
2291-2297
1973
Rattus norvegicus
brenda
Tilgmann, C.; Kalkkinen, N.
Purification and partial characterization of rat liver soluble catechol-O-methyltransferase
FEBS Lett.
264
95-99
1990
Homo sapiens, Rattus norvegicus
brenda
Schultz, E.; Nissinen, E.
Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462
Biochem. Pharmacol.
38
3953-3956
1989
Rattus norvegicus
brenda
Rhee, J.; Myung Un, C.
Rat liver catechol-O-methyltransferase: Purification and general properties
Hanguk Saenghwahakhoe Chi
21
60-67
1988
Rattus norvegicus
-
brenda
Tunnicliff, G.; Ngo, T.T.
Kinetics of rat brain soluble catechol-O-methyltransferase and its inhibition by substrate analogues
Int. J. Biochem.
15
733-738
1983
Rattus norvegicus
brenda
Borchardt, R.T.; Huber, J.H.; Houston, M.
Catechol O-methyltransferase. 10. 5-Substituted 3-hydroxy-4-methoxybenzoic acids (isovanillic acids) and 5-substituted 3-hydroxy-4-methoxybenzaldehydes (isovanillins) as potential inhibitors
J. Med. Chem.
25
258-263
1982
Rattus norvegicus
brenda
Ulmanen, I.; Peranen, J.; Tenhunen, J.; Tilgmann, C.; Karhunen, T.; Panula, P.; Bernasconi, L.; Aubry, J.P.; Lundstrom, K.
Expression and intracellular localization of catechol O-methyltransferase in transfected mammalian cells
Eur. J. Biochem.
243
452-459
1997
Homo sapiens, Rattus norvegicus
brenda
Karhunen, T.; Tilgmann, C.; Ulmanen, I.; Julkunen, I.; Panula, P.
Distribution of catechol-O-methyltransferase enzyme in rat tissues
J. Histochem. Cytochem.
42
1079-1090
1994
Rattus norvegicus
brenda
Weinshilboum, R.M.; Otterness, D.M.; Szumlanski, C.L.
Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase
Annu. Rev. Pharmacol. Toxicol.
39
19-52
1999
Rattus norvegicus, Homo sapiens (P21964)
brenda
Bonifacio, M.J.; Vieira-Coelho, M.A.; Borges, N.; Soares-da-Silva, P.
Kinetics of rat brain and liver solubilized membrane-bound catechol-O-methyltransferase
Arch. Biochem. Biophys.
384
361-367
2000
Rattus norvegicus
brenda
Bonifacio, M.J.; Vieira-Coelho, M.A.; Soares-da-Silva, P.
Expression and characterization of rat soluble catechol-O-methyltransferase fusion protein
Protein Expr. Purif.
23
106-112
2001
Rattus norvegicus, Rattus norvegicus S-COMT
brenda
Tilgmann, C.; Ulmanen, I.
Purification methods of mammalian catechol-O-methyltransferases
J. Chromatogr. B
684
147-161
1996
Homo sapiens, Rattus norvegicus
brenda
Borges, N.; Vieira-Coelho, M.A.; Parada, A.; Soares-Da-Silva, P.
Rat liver catechol-O-methyltransferase kinetics and assay methodology
J. Enzyme Inhib.
13
473-483
1998
Rattus norvegicus
brenda
Zheng, Y.; Bruice, T.C.
A theoretical examiniation of the factors controlling the catalytic efficiency of a transmethylation enzyme: Catechol O-methyltransferase
J. Am. Chem. Soc.
119
8137-8145
1997
Rattus norvegicus
-
brenda
Masuda, M.; Tsunoda, M.; Imai, K.
High-performance liquid chromatography-fluorescent assay of catechol-O-methyltransferase activity in rat brain
Anal. Bioanal. Chem.
376
1069-1073
2003
Rattus norvegicus
brenda
Tsunoda, M.; Imai, K.
An assay for determination of rat adrenal catechol-O-methyltransferase activity: comparison of spontaneously hypertensive rats and Wistar-Kyoto rats
Anal. Bioanal. Chem.
380
887-890
2004
Rattus norvegicus
brenda
Lu, H.; Meng, X.; Yang, C.S.
Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate
Drug Metab. Dispos.
31
572-579
2003
Homo sapiens, Rattus norvegicus, Sus scrofa
brenda
Bonifacio, M.J.; Vieira-Coelho, M.A.; Soares-da-Silva, P.
Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor
Eur. J. Pharmacol.
460
163-170
2003
Rattus norvegicus
brenda
Zaccharia L.C.; Dubey, R.K.; Mi, Z.; Jackson, E.K.
Methylation of 2-hydroxyestradiol in isolated organs
Hypertension
42
82-87
2003
Rattus norvegicus
brenda
Hirano, Y.; Tsunoda, M.; Shimosawa, T.; Fujita, T.; Funatsu, T.
Measurement of catechol-O-methyltransferase activity in the brain of Dahl salt-sensitive rats
Biol. Pharm. Bull.
30
2178-2180
2007
Rattus norvegicus
brenda
Bonifacio, M.J.; Palma, P.N.; Almeida, L.; Soares-da-Silva, P.
Catechol-O-methyltransferase and its inhibitors in Parkinsons disease
CNS Drug Rev.
13
352-379
2007
Oryctolagus cuniculus, Homo sapiens, Mus musculus, Sus scrofa, Rattus norvegicus (P22734)
brenda
Hirano, Y.; Tsunoda, M.; Shimosawa, T.; Matsui, H.; Fujita, T.; Funatsu, T.
Suppression of catechol-O-methyltransferase activity through blunting of alpha2-adrenoceptor can explain hypertension in Dahl salt-sensitive rats
Hypertens. Res.
30
269-278
2007
Homo sapiens, Rattus norvegicus
brenda
Rutherford, K.; Le Trong, I.; Stenkamp, R.E.; Parson, W.W.
Crystal structures of human 108V and 108M catechol O-methyltransferase
J. Mol. Biol.
380
120-130
2008
Sus scrofa, Homo sapiens (P21964), Homo sapiens, Rattus norvegicus (P22734)
brenda
Helkamaa, T.; Reenilae, I.; Tuominen, R.K.; Soinila, S.; Vaeaenaenen, A.; Tilgmann, C.; Rauhala, P.
Increased catechol-O-methyltransferase activity and protein expression in OX-42-positive cells in the substantia nigra after lipopolysaccharide microinfusion
Neurochem. Int.
51
412-423
2007
Rattus norvegicus
brenda
Nackley, A.G.; Tan, K.S.; Fecho, K.; Flood, P.; Diatchenko, L.; Maixner, W.
Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta 2- and beta 3-adrenergic receptors
Pain
128
199-208
2007
Rattus norvegicus
brenda
Wentz, M.J.; Shi, S.Q.; Shi, L.; Salama, S.A.; Harirah, H.M.; Fouad, H.; Garfield, R.E.; Al-Hendy, A.
Treatment with an inhibitor of catechol-O-methyltransferase activity reduces preterm birth and impedes cervical resistance to stretch in pregnant rats
Reproduction
134
831-839
2007
Rattus norvegicus
brenda
Tsuji, E.; Okazaki, K.; Takeda, K.
Crystal structures of rat catechol-O-methyltransferase complexed with coumarine-based inhibitor
Biochem. Biophys. Res. Commun.
378
494-497
2009
Rattus norvegicus (P22734)
brenda
Overbye, A.; Seglen, P.O.
Phosphorylated and non-phosphorylated forms of catechol O-methyltransferase in rat liver, brain and other tissues
Biochem. J.
417
535-545
2009
Rattus norvegicus
brenda
Reenilae, I.; Rauhala, P.
Simultaneous analysis of catechol-O-methyl transferase activity, S-adenosylhomocysteine and adenosine
Biomed. Chromatogr.
24
294-300
2010
Rattus norvegicus
brenda
Tsuji, E.; Okazaki, K.; Isaji, M.; Takeda, K.
Crystal structures of the apo and holo form of rat catechol-O-methyltransferase
J. Struct. Biol.
165
133-139
2009
Rattus norvegicus (P22734)
brenda
Meyers, B.; DAgostino, A.; Walker, J.; Kritzer, M.
Gonadectomy and hormone replacement exert region- and enzyme isoform-specific effects on monoamine oxidase and catechol-O-methyltransferase activity in prefrontal cortex and neostriatum of adult male rats
Neuroscience
165
850-862
2010
Rattus norvegicus
brenda
Ellermann, M.; Lerner, C.; Burgy, G.; Ehler, A.; Bissantz, C.; Jakob-Roetne, R.; Paulini, R.; Allemann, O.; Tissot, H.; Gruenstein, D.; Stihle, M.; Diederich, F.; Rudolph, M.G.
Catechol-O-methyltransferase in complex with substituted 3-deoxyribose bisubstrate inhibitors
Acta Crystallogr. Sect. D
68
253-260
2012
Rattus norvegicus (P22734)
brenda
Ellermann, M.; Paulini, R.; Jakob-Roetne, R.; Lerner, C.; Borroni, E.; Roth, D.; Ehler, A.; Schweizer, W.B.; Schlatter, D.; Rudolph, M.G.; Diederich, F.
Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors
Chemistry
17
6369-6381
2011
Rattus norvegicus
brenda
Kiss, L.E.; Ferreira, H.S.; Torrao, L.; Bonifacio, M.J.; Palma, P.N.; Soares-da-Silva, P.; Learmonth, D.A.
Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase
J. Med. Chem.
53
3396-3411
2010
Rattus norvegicus
brenda
Robinson, R.G.; Smith, S.M.; Wolkenberg, S.E.; Kandebo, M.; Yao, L.; Gibson, C.R.; Harrison, S.T.; Polsky-Fisher, S.; Barrow, J.C.; Manley, P.J.; Mulhearn, J.J.; Nanda, K.K.; Schubert, J.W.; Trotter, B.W.; Zhao, Z.; Sanders, J.M.; Smith, R.F.; McLoughlin, D.; Sharma, S.; Hall, D.L.; Walker, T.L.; Kershner, J.L.; , B.
Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates
ACS Chem. Neurosci.
3
129-140
2012
Homo sapiens, Rattus norvegicus
brenda
Weinert, C.; Wiese, S.; Rawel, H.; Esatbeyoglu, T.; Winterhalter, P.; Homann, T.; Kulling, S.
Methylation of catechins and procyanidins by rat and human catechol-o-methyltransferase: Metabolite profiling and molecular modeling studies
Drug Metab. Dispos.
40
353-359
2012
Homo sapiens, Rattus norvegicus
brenda
Garcia-Meseguer, R.; Zinovjev, K.; Roca, M.; Ruiz-Pernia, J.J.; Tunon, I.
Linking electrostatic effects and protein motions in enzymatic catalysis. A theoretical analysis of catechol O-methyltransferase
J. Phys. Chem. B
119
873-882
2015
Rattus norvegicus (P22734)
brenda
Schendzielorz, N.; Oinas, J.P.; Myoehaenen, T.T.; Reenilae, I.; Raasmaja, A.; Maennistoe, P.T.
Catechol-O-methyltransferase (COMT) protein expression and activity after dopaminergic and noradrenergic lesions of the rat brain
PLoS ONE
8
e61392
2013
Rattus norvegicus
brenda
Qi, Q.; Cao, L.; Li, F.; Wang, H.; Liu, H.; Hao, H.; Hao, K.
Salvianolic acid B as a substrate and weak catechol-O-methyltransferase inhibitor in rats
Xenobiotica
45
820-827
2015
Rattus norvegicus
brenda
Law, B.J.; Bennett, M.R.; Thompson, M.L.; Levy, C.; Shepherd, S.A.; Leys, D.; Micklefield, J.
Effects of active-site modification and quaternary structure on the regioselectivity of catechol-O-methyltransferase
Angew. Chem. Int. Ed. Engl.
55
2683-2687
2016
Rattus norvegicus (P22734)
brenda